GLP1R and obesity disorder: Proglucagon‐derived peptides, glucagon, and the incretin hormones GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP), represent attractive targets for managing obesity and metabolic disorders53, 54, 55, 56 because they may play a direct role in multiple mechanisms involved in the disease, including satiety, energy homeostasis, and lipolytic activity.46, 57, 58, 59